Biometric Screening Measurements Explained: BMI, Lipid Panel, A1C, Blood Pressure and More
A biometric screening is not a diagnosis or a substitute for ongoing medical care. It is a structured opportunity for an individual to learn selected health measurements, receive private education, and decide whether to follow up with a clinician. For benefits teams, the value is program design: screening data can help build a health risk assessment (HRA), target aggregate education, and administer a compliant participation incentive. The discipline is to distinguish what a measure indicates from what it proves. Employees need their individual results and appropriate referral language. Employers need de-identified, aggregated patterns that help them plan benefits and wellness support without seeing anyone’s clinical record.
The core measurements at a glance
| Measurement | What it measures | Common workplace use |
|---|---|---|
| Height, weight, BMI | weight relative to height | general risk-screening conversation |
| Waist circumference | central adiposity | optional cardiometabolic risk context |
| Blood pressure | force of blood against artery walls | hypertension risk flag and referral guidance |
| Lipid panel | cholesterol and triglyceride measures | cardiovascular risk conversation |
| Glucose | blood sugar at a point in time | diabetes-risk screening context |
| A1C | average glucose over roughly two to three months | diabetes and prediabetes screening context |
Selection should reflect the employer’s goals, clinical workflow, population, budget, and the availability of meaningful follow-up resources. More tests are not inherently better. A short, well-explained panel with a referral plan is usually more valuable than a broad panel that produces confusion.
BMI: a screening tool, not a diagnosis
Body mass index, or BMI, is calculated from height and weight. It is often used because it is simple and standardized. For most adults, the CDC describes BMI categories as underweight below 18.5, healthy weight 18.5 to less than 25, overweight 25 to less than 30, and obesity 30 or higher.CDC adult BMI categories
BMI does not measure body composition, fitness, diet, or metabolic health directly. A muscular person may have a high BMI without high body fat, while someone in a lower BMI range can still have cardiovascular or metabolic risk. It should never be used by an employer to judge an employee, set employment conditions, or infer a diagnosis. In a screening, it is one conversation starter alongside blood pressure, lab values, family history, and the employee’s own clinician relationship.
Waist circumference and body composition
Some programs add waist circumference or body-composition measures because abdominal fat distribution can provide additional context. These measures require privacy, trained staff, consistent technique, and careful communication. If the employer cannot provide a private and respectful process, omitting them is better than collecting a number without a useful follow-up path.
Blood pressure: why technique matters
Blood pressure has two values: systolic pressure, the top number, and diastolic pressure, the bottom number. Current ACC/AHA categories describe normal blood pressure as less than 120/80 mm Hg; elevated as systolic 120–129 with diastolic below 80; stage 1 hypertension as systolic 130–139 or diastolic 80–89; and stage 2 hypertension as systolic at least 140 or diastolic at least 90.ACC/AHA blood pressure categories
A screening reading is a snapshot. Caffeine, nicotine, activity, stress, conversation, cuff size, posture, and inadequate rest can affect it. Clinical diagnosis typically requires properly obtained readings over more than one occasion. A quality onsite workflow seats the participant, uses the correct cuff, repeats unexpectedly high readings according to protocol, and gives private referral guidance. The employer should not see the reading.
Lipid panel: total cholesterol is only one number
A standard lipid panel may include total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. LDL-C is often discussed as a key contributor to atherosclerotic cardiovascular risk. HDL-C and triglycerides add context, but none of these values should be interpreted in isolation. Age, blood pressure, diabetes status, smoking, medications, family history, and other factors matter in a clinician’s risk discussion.
Many workplace panels are obtained by fingerstick point-of-care testing; others are sent to a laboratory. Whether fasting is required depends on the panel and the clinical purpose. The program should tell employees what preparation is expected and should not label a result “good” or “bad” without context. The most useful result conversation explains the value, identifies whether it is outside a reference or decision threshold, and encourages discussion with a personal clinician when appropriate.
Glucose and A1C: related but different measures
Glucose measures the concentration of sugar in the blood at that moment. Its interpretation depends heavily on whether the person fasted, when they last ate, illness, and medication use. It can be helpful for screening discussions but is not a stand-alone diagnosis from a workplace event.
A1C estimates average blood glucose over the prior two to three months. The American Diabetes Association (ADA) lists normal A1C as below 5.7%, prediabetes as 5.7% through 6.4%, and diabetes at 6.5% or higher, subject to clinical confirmation in the absence of unequivocal hyperglycemia.ADA diabetes diagnosis Certain conditions, including some hemoglobin variants, anemia, kidney disease, pregnancy, and recent blood loss or transfusion, can affect A1C interpretation. That is why a screening should use referral language, not diagnose an employee.
For incentives, it is particularly important not to reward or penalize a person simply for having a certain A1C or glucose result. Health outcomes reflect many factors, including conditions and treatments that are not under an employee’s immediate control.
How measurements fit an HRA and incentive design
An HRA combines self-reported health information with optional screening information to provide individualized feedback and identify aggregate opportunities. The architecture should make clear which fields are voluntary, who receives them, how long they are retained, and how an employee can access results. Clinical results should flow to the individual through a secure portal or private report. Employer reporting should use appropriately de-identified or aggregated information and minimum-cell-size rules.
Participation-based incentives are generally easier to administer because the reward is tied to completing a screening or education action, not to changing a medical result. Outcome-based programs require more careful legal and clinical design, including reasonable alternatives where required. The ADA and EEOC considerations should be reviewed with counsel and benefits advisers before launching any health-contingent program.
Build a result-to-action pathway
Before ordering tests, decide what happens next. A sound pathway includes: immediate private education; urgent escalation criteria for the clinical team; employee access to results; suggested follow-up timeframes; optional coaching, navigation, or primary-care resources; and a communication plan that does not expose individual results to managers.
This design keeps the screening in its proper role. It is an access point and a prompt for preventive care, not an employer-owned medical file.
How PicMed helps
PicMed’s corporate biometric screening service can be configured around appropriate measurements, private education, secure results access, and aggregate reporting that supports employer wellness planning.
Frequently asked questions
Does a biometric screening diagnose diabetes or hypertension?
No. Screening values can identify a reason to seek clinical follow-up, but diagnosis and treatment decisions require an appropriate clinical evaluation.
Is BMI a measure of body fat?
No. BMI is a height-and-weight screening measure. It does not directly measure body composition or individual health status.
What is the difference between glucose and A1C?
Glucose is a point-in-time blood sugar measure. A1C estimates average glucose over approximately two to three months.
Can employers see individual results?
They should not receive individual clinical results. Program reporting should be aggregated and designed to protect privacy.